WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsTela Bio Inc (TELA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 26667% more annual revenue ($20.63B vs $77.06M). GEHC leads profitability with a 10.1% profit margin vs -50.6%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

TELA

Avoid

31

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -5.04
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for TELA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

TELA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

TELA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.90M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-6.8%2/10

ROE of -6.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : TELA

TELA has a balanced fundamental profile.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : TELA

The primary concerns for TELA are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 26.98 is elevated, increasing financial risk.

Key Dynamics to Monitor

GEHC profiles as a value stock while TELA is a turnaround play — different risk/reward profiles.

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

TELA is growing revenue faster at 9.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Tela Bio Inc

HEALTHCARE · MEDICAL DEVICES · USA

TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?